

# CITATION REPORT

List of articles citing

Economic evaluation of biosimilars for reimbursement purposes - what, when, how?

DOI: 10.1080/20016689.2020.1739509

Journal of Market Access & Health Policy, 2020, 8, 1739509.

**Source:** <https://exaly.com/paper-pdf/77640494/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	A health economic guide to market access of biosimilars. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 9-17	5.4	6
4	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , <b>2021</b> , 13, 1868078	6.6	6
3	The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?. <i>Pharmaceuticals</i> , <b>2021</b> , 14,	5.2	1
2	Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 644187	5.6	3
1	Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking. <i>Frontiers in Pharmacology</i> , 13,	5.6	1